{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:32:31Z","timestamp":1785148351996,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Basic Clin. Androl."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Valganciclovir, the prodrug of ganciclovir, is an antiviral agent targeting herpes viruses. It is indicated for the prophylaxis or treatment of cytomegalovirus infections in immunocompromised patients. Pre-clinical studies state ganciclovir as a mutagenic, teratogenic, reprotoxic drug that can rarely alter male fertility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>Mr S. had experienced primo-secondary infertility with his partner for 12 months. He had no significant medical history aside from exertional asthma and achieved semen analysis at age 33, revealing normal sperm concentration (110 million\/mL, 383 million\/ejaculate) with normal progressive motility (50%).<\/jats:p>\n                    <jats:p>One month after, during a trail race, he reported malignant exertional hyperthermia (41.7\u00b0C) leading to multi-organ failure and coma and requiring intensive care and an emergency hepatic transplant. Post-transplant, anti-rejection therapy was started including tacrolimus, mycophenolate mofetil, co-trimoxazole, and valganciclovir.<\/jats:p>\n                    <jats:p>Six months after the transplant, he undertook sperm cryopreservation. Repeated semen analysis confirmed azoospermia.<\/jats:p>\n                    <jats:p>Semen analysis 12 weeks after discontinuation of valganciclovir showed rare motile sperm, allowing cryopreservation. Subsequent analyses showed significant improvement, with concentration reaching 10.1 M\/mL 14 weeks later and 70 M\/mL 24 weeks later, allowing ICSI with fresh sperm. This resulted in a successful pregnancy and live birth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We report a case of azoospermia observed after valganciclovir treatment. Based on a review of the literature, the azoospermia observed in this patient could be attributed to valganciclovir.<\/jats:p>\n                    <jats:p>However, alternative explanations such as fever or infectious complications cannot be ruled out. Valganciclovir is reprotoxic and should be replaced with an alternative drug in men planning to conceive.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12610-026-00299-0","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:49:28Z","timestamp":1783331368000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A case of secretory azoospermia: is valganciclovir responsible?"],"prefix":"10.1186","volume":"36","author":[{"given":"Louise","family":"Michenaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Lapoirie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elo\u00efse","family":"Fraison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Salle-Leyris-de-Campredon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Plotton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Giscard-d\u2019Estaing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"8","key":"299_CR1","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1177\/00912709922008452","volume":"39","author":"D Jung","year":"1999","unstructured":"Jung D, Dorr A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol. 1999;39(8):800\u20134.","journal-title":"J Clin Pharmacol"},{"key":"299_CR2","unstructured":"Drugs.com. ValGANciclovir monograph for professionals. Available from: https:\/\/www.drugs.com\/monograph\/valganciclovir.html.\u00a0Cited 10 Jul 2024."},{"key":"299_CR3","doi-asserted-by":"crossref","unstructured":"Faqi AS, Klug A, Merker HJ, Chahoud I. Ganciclovir induces reproductive hazards in male rats after short-term exposure. Hum Exp Toxicol. 1997;16(9):505\u201311.","DOI":"10.1177\/096032719701600905"},{"issue":"6","key":"299_CR4","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.3390\/clinpract14060191","volume":"14","author":"W Szulc","year":"2024","unstructured":"Szulc W, Szyd\u0142owska N, Smyk JM, Majewska A. Progress and challenges in the management of congenital cytomegalovirus infection. Clin Pract. 2024;14(6):2445\u201362.","journal-title":"Clin Pract"},{"key":"299_CR5","unstructured":"Geneva: World Health Organization. WHO laboratory manual for the examination and processing of human semen, sixth edition. Licence CC -NC-SA 30 IGO. 2021. Available from: https:\/\/www.who.int\/publications-detail-redirect\/9789240030787. Cited 3 Jan 2024."},{"key":"299_CR6","doi-asserted-by":"crossref","unstructured":"Kotton CN, Kumar D, Manuel O, Chou S, Hayden RT, Danziger-Isakov L et al. The fourth international consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation. 2025;109(7):1066\u2013110.","DOI":"10.1097\/TP.0000000000005374"},{"key":"299_CR7","doi-asserted-by":"crossref","unstructured":"Mieda K, Hori S, Tomizawa M, Inoue K, Yoneda T, Nitta Y, et al. Transient azoospermia induced by valganciclovir treatment for cytomegalovirus infection in a reproductive male after kidney transplant: a case report. IJU Case Rep. 2025;8(4):431\u20134.","DOI":"10.1002\/iju5.70060"},{"key":"299_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.mrgentox.2016.10.002","volume":"810","author":"H Ferjani","year":"2016","unstructured":"Ferjani H, Draz H, Abid S, Achour A, Bacha H, Boussema-Ayed I. Combination of tacrolimus and mycophenolate mofetil induces oxidative stress and genotoxicity in spleen and bone marrow of Wistar rats. Mutat Res Genet Toxicol Environ Mutagen. 2016;810:48\u201355.","journal-title":"Mutat Res Genet Toxicol Environ Mutagen"},{"key":"299_CR9","doi-asserted-by":"crossref","unstructured":"Kurtoglu EL, Yuksel S. Genotoxic effects of tacrolimus on human lymphocyte cells. Genetika. 2012;48(6):762\u20137.","DOI":"10.1134\/S1022795412050134"},{"issue":"2","key":"299_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.etp.2014.11.008","volume":"67","author":"HL Cili\u00e3o","year":"2015","unstructured":"Cili\u00e3o HL, Ribeiro DL, Camargo-Godoy RBO, Specian AFL, Serpeloni JM, C\u00f3lus IMS. Cytotoxic and genotoxic effects of high concentrations of the immunosuppressive drugs cyclosporine and tacrolimus in MRC-5 cells. Exp Toxicol Pathol Off J Ges Toxikol Pathol. 2015;67(2):179\u201387.","journal-title":"Exp Toxicol Pathol Off J Ges Toxikol Pathol"},{"issue":"5","key":"299_CR11","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.semarthrit.2018.07.011","volume":"48","author":"M Mouyis","year":"2019","unstructured":"Mouyis M, Flint JD, Giles IP. Safety of anti-rheumatic drugs in men trying to conceive: A systematic review and analysis of published evidence. Semin Arthritis Rheum. 2019;48(5):911\u201320.","journal-title":"Semin Arthritis Rheum"},{"key":"299_CR12","unstructured":"JAMP Pharma Corporation. Product monograph including patient medication information: JAMP-Mycophenolate. Montr\u00e9al: JAMP Pharma Corporation; 2023."},{"key":"299_CR13","unstructured":"European Medicines Agency. Mycophenolate mofetil Teva: EPAR product information. 2024. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mycophenolate-mofetil-teva-epar-product-information_en.pdf?utm_source=chatgpt.com."},{"issue":"6","key":"299_CR14","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0890-6238(01)00178-2","volume":"15","author":"AE Czeizel","year":"2001","unstructured":"Czeizel AE, Rockenbauer M, S\u00f8rensen HT, Olsen J. The teratogenic risk of trimethoprim-sulfonamides: a population based case-control study. Reprod Toxicol Elmsford N. 2001;15(6):637\u201346.","journal-title":"Reprod Toxicol Elmsford N"},{"key":"299_CR15","doi-asserted-by":"crossref","unstructured":"Hargreaves CA, Rogers S, Hills F, Rahman F, Howell RJ, Homa ST. Effects of co-trimoxazole, erythromycin, amoxycillin, tetracycline and chloroquine on sperm function in vitro. Hum Reprod Oxf Engl. 1998;13(7):1878\u201386.","DOI":"10.1093\/humrep\/13.7.1878"},{"key":"299_CR16","doi-asserted-by":"crossref","unstructured":"R\u00fcegg L, Pluma A, Hamroun S, Cecchi I, Perez-Garcia LF, Anderson PO, et al. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. Ann Rheum Dis. 2025;84(6):910\u201326.","DOI":"10.1016\/j.ard.2025.02.023"},{"issue":"10","key":"299_CR17","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1136\/gutjnl-2016-312123","volume":"66","author":"BM N\u00f8rg\u00e5rd","year":"2017","unstructured":"N\u00f8rg\u00e5rd BM, Magnussen B, Larsen MD, Friedman S. Reassuring results on birth outcomes in children fathered by men treated with azathioprine\/6-mercaptopurine within 3\u2005months before conception: a nationwide cohort study. Gut. 2017;66(10):1761\u20136.","journal-title":"Gut"},{"issue":"6","key":"299_CR18","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/fcp.12153","volume":"29","author":"D Dinter","year":"2015","unstructured":"Dinter D, Gajski G, Domijan AM, Garaj-Vrhovac V. Cytogenetic and oxidative status of human lymphocytes after exposure to clinically relevant concentrations of antimalarial drugs Atovaquone and proguanil hydrochloride in vitro. Fundam Clin Pharmacol. 2015;29(6):575\u201385.","journal-title":"Fundam Clin Pharmacol"},{"key":"299_CR19","unstructured":"Atovaquone Glenmark 750\u00a0mg\/5\u00a0ml oral suspension - Summary of Product Characteristics (SmPC). - (emc). Available from: https:\/\/www.medicines.org.uk\/emc\/product\/9901\/smpc#gref. Cited 2 Jul 2024."},{"key":"299_CR20","doi-asserted-by":"crossref","unstructured":"Semet M, Paci M, Sa\u00efas-Magnan J, Metzler-Guillemain C, Boissier R, Lejeune H, et al. The impact of drugs on male fertility: a review. Andrology. 2017;5(4):640\u201363.","DOI":"10.1111\/andr.12366"},{"issue":"1","key":"299_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/sj.cgt.7700106","volume":"7","author":"R Thust","year":"2000","unstructured":"Thust R, Tomicic M, Kl\u00f6cking R, Voutilainen N, Wutzler P, Kaina B. Comparison of the genotoxic and apoptosis-inducing properties of ganciclovir and penciclovir in Chinese hamster ovary cells transfected with the thymidine kinase gene of herpes simplex virus-1: implications for gene therapeutic approaches. Cancer Gene Ther. 2000;7(1):107\u201317.","journal-title":"Cancer Gene Ther"},{"key":"299_CR22","doi-asserted-by":"crossref","unstructured":"Haynes P, Lambert TR, Mitchell ID. Comparative in-vivo genotoxicity of antiviral nucleoside analogues; penciclovir, acyclovir, ganciclovir and the xanthine analogue, caffeine, in the mouse bone marrow micronucleus assay. Mutat Res. 1996;369(1\u20132):65\u201374.","DOI":"10.1016\/S0165-1218(96)90049-X"},{"issue":"1","key":"299_CR23","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13073-022-01131-w","volume":"14","author":"H Fang","year":"2022","unstructured":"Fang H, Yan HHN, Bilardi RA, Flensburg C, Yang H, Barbour JA, et al. Ganciclovir-induced mutations are present in a diverse spectrum of post-transplant malignancies. Genome Med. 2022;14(1):124.","journal-title":"Genome Med"},{"issue":"6","key":"299_CR24","doi-asserted-by":"publisher","first-page":"10714","DOI":"10.18632\/oncotarget.12956","volume":"8","author":"J Ding","year":"2016","unstructured":"Ding J, Shang X, Zhang Z, Jing H, Shao J, Fei Q, et al. FDA-approved medications that impair human spermatogenesis. Oncotarget. 2016;8(6):10714\u201325.","journal-title":"Oncotarget"},{"issue":"1","key":"299_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1128\/AAC.39.1.56","volume":"39","author":"J Neyts","year":"1995","unstructured":"Neyts J, J\u00e4hne G, Andrei G, Snoeck R, Winkler I, De Clercq E. In vivo antiherpesvirus activity of N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine. Antimicrob Agents Chemother. 1995;39(1):56\u201360.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"299_CR26","first-page":"310","volume":"33","author":"P McLeroth","year":"2020","unstructured":"McLeroth P, Paduch DA, Abt M, Hughes R, Moore S, Mudie N. Effects of valganciclovir on spermatogenesis in renal transplant patients - results of a multicenter prospective nonrandomized study. Transpl Int Off J Eur Soc Organ Transpl. 2020;33(3):310\u201320.","journal-title":"Transpl Int Off J Eur Soc Organ Transpl"},{"key":"299_CR27","doi-asserted-by":"crossref","unstructured":"Jensen NB, Justesen SD, Larsen A, Ernst E, Pedersen LH. A systematic overview of the spermatotoxic and genotoxic effects of methotrexate, ganciclovir and mycophenolate mofetil. Acta Obstet Gynecol Scand. 2021 Sept;100(9):1557\u201380.","DOI":"10.1111\/aogs.14151"},{"issue":"1","key":"299_CR28","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1080\/09273948.2024.2356057","volume":"33","author":"AM Dheyab","year":"2025","unstructured":"Dheyab AM, Albloushi AF, Al-Zuabi A, AlTariqi SM, Tobaigy MF, Alfawaz A, et al. Long-term efficacy of oral valganciclovir in presumed cytomegalovirus unilateral hypertensive anterior uveitis. Ocul Immunol Inflamm. 2025;33(1):72\u20139.","journal-title":"Ocul Immunol Inflamm"},{"key":"299_CR29","unstructured":"Endo Ventures Ltd. Product monograph including patient medication information: Envarsus PA\u00ae. Dublin (Ireland): Endo Ventures Ltd.; 2020."},{"issue":"2","key":"299_CR30","first-page":"273","volume":"2","author":"VD Oliveira","year":"2004","unstructured":"Oliveira VD, Zankl H, Rath T. Mutagenic and cytotoxic effects of immunosuppressive drugs on human lymphocyte cultures. Exp Clin Transpl Off J Middle East Soc Organ Transpl. 2004;2(2):273\u20139.","journal-title":"Exp Clin Transpl Off J Middle East Soc Organ Transpl"},{"issue":"5","key":"299_CR31","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1097\/00007890-199903150-00021","volume":"67","author":"MD Pescovitz","year":"1999","unstructured":"Pescovitz MD. Absence of teratogenicity of oral ganciclovir used during early pregnancy in a liver transplant recipient. Transplantation. 1999;67(5):758\u20139.","journal-title":"Transplantation"},{"issue":"5","key":"299_CR32","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00430-017-0512-3","volume":"206","author":"V Seidel","year":"2017","unstructured":"Seidel V, Feiterna-Sperling C, Siedentopf JP, Hofmann J, Henrich W, B\u00fchrer C, et al. Intrauterine therapy of cytomegalovirus infection with valganciclovir: review of the literature. Med Microbiol Immunol (Berl). 2017;206(5):347\u201354.","journal-title":"Med Microbiol Immunol (Berl)"},{"issue":"5","key":"299_CR33","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1093\/jac\/dkad087","volume":"78","author":"A Contejean","year":"2023","unstructured":"Contejean A, Leruez-Ville M, Treluyer JM, Tsatsaris V, Ville Y, Charlier C, et al. Assessing the risk of adverse pregnancy outcomes and birth defects reporting in women exposed to ganciclovir or valganciclovir during pregnancy: a pharmacovigilance study. J Antimicrob Chemother. 2023;78(5):1265\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"299_CR34","doi-asserted-by":"crossref","unstructured":"Khalil A, Heath PT, Jones CE, Soe A, Ville YG. The Royal College of Obstetricians and Gynaecologists. Congenital cytomegalovirus infection: update on screening, diagnosis and treatment: scientific impact paper No. 56. BJOG Int J Obstet Gynaecol [Internet]. 2025;132(2). Available from: https:\/\/obgyn.onlinelibrary.wiley.com \/https:\/\/doi.org\/10.1111\/1471-0528.17966.\u00a0. Cited 27 Sept 2025.","DOI":"10.1111\/1471-0528.17966"},{"issue":"2","key":"299_CR35","first-page":"111","volume":"40","author":"B B\u00e9gaud","year":"1985","unstructured":"B\u00e9gaud B, Evreux JC, Jouglard J, Lagier G. [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France]. Therapie. 1985;40(2):111\u20138.","journal-title":"Therapie"},{"key":"299_CR36","doi-asserted-by":"crossref","unstructured":"Naranjo A, Busto U, Sellers E, Sandor P, ruiz itza, Roberts E et al. A method of estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981 Sept 1;30:239\u201345.","DOI":"10.1038\/clpt.1981.154"}],"container-title":["Basic and Clinical Andrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12610-026-00299-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12610-026-00299-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12610-026-00299-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:50:13Z","timestamp":1783331413000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12610-026-00299-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["299"],"URL":"https:\/\/doi.org\/10.1186\/s12610-026-00299-0","relation":{},"ISSN":["2051-4190"],"issn-type":[{"value":"2051-4190","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"18 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional ethics committee (authorization number 25\u2013357).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}